PT1237575E - Antagonista de tnf-alfa e antagonista de lfa-1 para tratar a artrite reumatóide - Google Patents
Antagonista de tnf-alfa e antagonista de lfa-1 para tratar a artrite reumatóide Download PDFInfo
- Publication number
- PT1237575E PT1237575E PT00986377T PT00986377T PT1237575E PT 1237575 E PT1237575 E PT 1237575E PT 00986377 T PT00986377 T PT 00986377T PT 00986377 T PT00986377 T PT 00986377T PT 1237575 E PT1237575 E PT 1237575E
- Authority
- PT
- Portugal
- Prior art keywords
- antagonist
- lfa
- tnf
- alpha
- rheumatoid arthritis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychiatry (AREA)
- Biophysics (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17069699P | 1999-12-14 | 1999-12-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT1237575E true PT1237575E (pt) | 2008-11-17 |
Family
ID=22620900
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT00986377T PT1237575E (pt) | 1999-12-14 | 2000-12-14 | Antagonista de tnf-alfa e antagonista de lfa-1 para tratar a artrite reumatóide |
Country Status (15)
Country | Link |
---|---|
US (3) | US20010031260A1 (pt) |
EP (1) | EP1237575B1 (pt) |
JP (1) | JP2003517022A (pt) |
KR (1) | KR100567292B1 (pt) |
CN (1) | CN1409639A (pt) |
AT (1) | ATE403437T1 (pt) |
AU (1) | AU768324B2 (pt) |
CA (1) | CA2394862C (pt) |
DE (1) | DE60039783D1 (pt) |
DK (1) | DK1237575T3 (pt) |
ES (1) | ES2311483T3 (pt) |
IL (1) | IL149890A0 (pt) |
NZ (1) | NZ519222A (pt) |
PT (1) | PT1237575E (pt) |
WO (1) | WO2001043773A1 (pt) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001287000A1 (en) | 2000-09-01 | 2002-03-13 | The Center For Blood Research, Inc. | Modified polypeptides stabilized in a desired conformation and methods for producing same |
CN1507354A (zh) * | 2001-03-02 | 2004-06-23 | ͨ��ҽ�ƹ�˾ | 通过给予整合蛋白αvβ3拮抗剂并与其它预防或治疗药剂配合来预防或者治疗炎性疾病或自身免疫疾病的方法 |
GB0111497D0 (en) * | 2001-05-11 | 2001-07-04 | Medical Res Council | Therapeutic methods |
EP3210624A1 (en) * | 2002-02-27 | 2017-08-30 | Immunex Corporation | Stabilized tnfr-fc composition comprising arginine |
PL215168B1 (pl) | 2002-02-27 | 2013-10-31 | Immunex Corp | Formulacja polipeptydowa |
US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
MXPA05003063A (es) * | 2002-09-20 | 2005-05-27 | Alcon Inc | Uso de inhibidores de la sintesis de citosina para el tratamiento de trastornos de ojos secos. |
CA2585024A1 (en) * | 2003-10-24 | 2005-05-06 | Azopax Therapeutics Llc | Macromer-melt formulations |
CA2544678C (en) | 2003-11-05 | 2013-12-31 | Sunesis Pharmaceuticals, Inc. | Modulators of cellular adhesion |
US8697139B2 (en) | 2004-09-21 | 2014-04-15 | Frank M. Phillips | Method of intervertebral disc treatment using articular chondrocyte cells |
US7871988B1 (en) * | 2005-01-04 | 2011-01-18 | Gp Medical, Inc. | Nanoparticles for protein drug delivery |
BRPI0610058A2 (pt) | 2005-05-16 | 2010-05-25 | Abbott Biotech Ltd | uso de inibidor de tnf para tratamento da poliartrite erosiva |
DK1881823T3 (en) * | 2005-05-17 | 2015-03-02 | Sarcode Bioscience Inc | COMPOSITION AND PROCEDURES FOR TREATMENT OF EYE DISORDERS |
EP1909831A4 (en) | 2005-06-14 | 2013-02-20 | Amgen Inc | PREPARATIONS OF SPONTANEOUS TAMPING PROTEINS |
US20070243132A1 (en) * | 2005-12-22 | 2007-10-18 | Apollo Life Sciences Limited | Transdermal delivery of pharmaceutical agents |
EP2666472A3 (en) | 2006-04-10 | 2014-04-02 | Abbott Biotechnology Ltd | Uses and compositions for treatment of psoriatic arthritis |
US9605064B2 (en) | 2006-04-10 | 2017-03-28 | Abbvie Biotechnology Ltd | Methods and compositions for treatment of skin disorders |
US8999337B2 (en) | 2007-06-11 | 2015-04-07 | Abbvie Biotechnology Ltd. | Methods for treating juvenile idiopathic arthritis by inhibition of TNFα |
MX2010004281A (es) | 2007-10-19 | 2010-09-10 | Sarcode Corp | Composiciones y metodos para el tratamiento de la retinopatia diabetica. |
EP2265124A4 (en) * | 2008-04-15 | 2011-12-28 | Sarcode Bioscience Inc | AEROSOLISED LFA-1 ANTAGONISTS FOR THE USE IN THE LOCAL TREATMENT OF IMMUNE DISEASES |
WO2009139817A2 (en) | 2008-04-15 | 2009-11-19 | Sarcode Corporation | Crystalline pharmaceutical and methods of preparation and use thereof |
JP2011521896A (ja) * | 2008-04-15 | 2011-07-28 | サーコード コーポレイション | 免疫関連障害に対する局部治療に使用するための局所lfa−1アンタゴニスト |
WO2011063127A1 (en) | 2009-11-18 | 2011-05-26 | University Of Medicine And Dentistry Of New Jersey | Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies |
HUE028283T2 (en) * | 2009-08-06 | 2016-12-28 | Anitox Corp | Water and food preservatives |
US8378105B2 (en) | 2009-10-21 | 2013-02-19 | Sarcode Bioscience Inc. | Crystalline pharmaceutical and methods of preparation and use thereof |
US9849192B2 (en) | 2009-11-18 | 2017-12-26 | Rutgers, The State University Of New Jersey | Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies |
JP2013537430A (ja) * | 2010-08-27 | 2013-10-03 | アニトックス コーポレーション | 抗菌性処方剤 |
AU2012326529A1 (en) | 2011-10-20 | 2014-04-03 | Anitox Corporation | Antimicrobial formulations with pelargonic acid |
KR20140097253A (ko) | 2011-11-30 | 2014-08-06 | 아니톡스 코포레이션 | 알데히드, 유기산 및 유기산 에스테르의 항미생물성 혼합물 |
JP6607780B2 (ja) | 2012-07-25 | 2019-11-20 | サルコード・バイオサイエンス・インコーポレイテッド | Lfa−1阻害剤およびその多形 |
WO2014046631A1 (en) | 2012-09-19 | 2014-03-27 | Tezcaner Aysen | CONTROLED DRUG DELIVERY SYSTEMS FOR ANTI-TNF-α |
WO2014055663A1 (en) * | 2012-10-02 | 2014-04-10 | Rutgers, The State University Of New Jersey | Specific delivery of toxins conjugated wtih antibodies to activated matriptase |
WO2016149139A1 (en) * | 2015-03-13 | 2016-09-22 | Samsung Bioepis Co., Ltd. | Anti-tnf-alpha polypeptide composition and use thereof |
RU2613056C1 (ru) * | 2016-03-14 | 2017-03-15 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Южно-Уральский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО ЮУГМУ Минздрава России) | Способ прогнозирования развития увеита у детей с ювенильным идиопатическим артритом |
CN108778274A (zh) | 2016-03-18 | 2018-11-09 | 新泽西鲁特格斯州立大学 | 用通过可体内裂解的连接部分与抗蛋白裂解酶抗体缀合的化学治疗剂靶向肿瘤细胞 |
US20180110856A1 (en) | 2016-10-21 | 2018-04-26 | Amgen Inc. | Pharmaceutical Formulations and Methods of Making the Same |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5672347A (en) * | 1984-07-05 | 1997-09-30 | Genentech, Inc. | Tumor necrosis factor antagonists and their use |
IL83878A (en) * | 1987-09-13 | 1995-07-31 | Yeda Res & Dev | Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it |
US5336603A (en) * | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
US5225538A (en) * | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
US5690933A (en) * | 1989-05-31 | 1997-11-25 | Glaxo Wellcome Inc. | Monoclonal antibodies for inducing tolerance |
US5605690A (en) * | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
NZ235148A (en) * | 1989-09-05 | 1991-12-23 | Immunex Corp | Tumour necrosis factor receptor protein and dna sequences |
US5945397A (en) * | 1989-09-05 | 1999-08-31 | Immunex Corporation | Purified p75 (type II) tumor necrosis factor receptor polypeptides |
US5994510A (en) * | 1990-12-21 | 1999-11-30 | Celltech Therapeutics Limited | Recombinant antibodies specific for TNFα |
US5919452A (en) * | 1991-03-18 | 1999-07-06 | New York University | Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies |
US5698195A (en) * | 1991-03-18 | 1997-12-16 | New York University Medical Center | Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies |
US5656272A (en) * | 1991-03-18 | 1997-08-12 | New York University Medical Center | Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies |
GB9115364D0 (en) * | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
MX9305070A (es) * | 1992-08-21 | 1994-04-29 | Genentech Inc | Compocicion farmaceutica que contiene un antagonista de lfa-1 para el tratamiento de transtornos o desordenes mediados por el lfa-1 |
JPH08505521A (ja) * | 1992-11-03 | 1996-06-18 | ジーン・シアーズ・プロプライアタリー・リミテッド | TNF−αリボザイムおよびTNF−αリボザイムにリンクした耐分解性mRNA誘導体 |
PT614984E (pt) * | 1993-03-05 | 2001-12-28 | Bayer Ag | Anticorpos humanos anti-tnf |
US5594106A (en) * | 1993-08-23 | 1997-01-14 | Immunex Corporation | Inhibitors of TNF-α secretion |
JPH09510952A (ja) * | 1993-10-06 | 1997-11-04 | ザ ケネディー インスティチュート オブ リューマトロジー | 自己免疫疾患および炎症性疾患の治療 |
JPH10130240A (ja) * | 1996-10-30 | 1998-05-19 | Dai Ichi Seiyaku Co Ltd | Icam−1産生阻害剤 |
DE69726878T2 (de) * | 1996-11-15 | 2004-10-21 | Kennedy Inst Of Rheumatology L | UNTERDRÜCKUNG VON TNFalpha UND IL-12 IN DER THERAPIE |
US6037454A (en) * | 1996-11-27 | 2000-03-14 | Genentech, Inc. | Humanized anti-CD11a antibodies |
DK1516629T3 (da) * | 1996-11-27 | 2013-06-03 | Genentech Inc | Humaniseret anti-CD-11a antibodies |
EP0942740B1 (en) * | 1996-12-06 | 2003-08-27 | Amgen Inc., | Combination therapy using a tnf binding protein for treating tnf-mediated diseases |
-
2000
- 2000-12-14 AU AU54397/01A patent/AU768324B2/en not_active Ceased
- 2000-12-14 JP JP2001544909A patent/JP2003517022A/ja active Pending
- 2000-12-14 EP EP00986377A patent/EP1237575B1/en not_active Expired - Lifetime
- 2000-12-14 ES ES00986377T patent/ES2311483T3/es not_active Expired - Lifetime
- 2000-12-14 PT PT00986377T patent/PT1237575E/pt unknown
- 2000-12-14 KR KR1020027007537A patent/KR100567292B1/ko not_active IP Right Cessation
- 2000-12-14 CN CN00817171A patent/CN1409639A/zh active Pending
- 2000-12-14 DK DK00986377T patent/DK1237575T3/da active
- 2000-12-14 AT AT00986377T patent/ATE403437T1/de not_active IP Right Cessation
- 2000-12-14 US US09/738,540 patent/US20010031260A1/en not_active Abandoned
- 2000-12-14 IL IL14989000A patent/IL149890A0/xx unknown
- 2000-12-14 CA CA2394862A patent/CA2394862C/en not_active Expired - Fee Related
- 2000-12-14 DE DE60039783T patent/DE60039783D1/de not_active Expired - Lifetime
- 2000-12-14 NZ NZ519222A patent/NZ519222A/en not_active IP Right Cessation
- 2000-12-14 WO PCT/US2000/033875 patent/WO2001043773A1/en active IP Right Grant
-
2005
- 2005-05-12 US US11/128,912 patent/US20050214291A1/en not_active Abandoned
-
2007
- 2007-07-26 US US11/828,977 patent/US20080031875A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20080031875A1 (en) | 2008-02-07 |
ATE403437T1 (de) | 2008-08-15 |
CA2394862C (en) | 2011-10-11 |
KR20020068372A (ko) | 2002-08-27 |
US20050214291A1 (en) | 2005-09-29 |
DE60039783D1 (de) | 2008-09-18 |
DK1237575T3 (da) | 2008-12-08 |
AU768324B2 (en) | 2003-12-11 |
NZ519222A (en) | 2004-04-30 |
IL149890A0 (en) | 2002-11-10 |
EP1237575B1 (en) | 2008-08-06 |
CN1409639A (zh) | 2003-04-09 |
WO2001043773A1 (en) | 2001-06-21 |
AU5439701A (en) | 2001-06-25 |
EP1237575A1 (en) | 2002-09-11 |
ES2311483T3 (es) | 2009-02-16 |
KR100567292B1 (ko) | 2006-04-04 |
JP2003517022A (ja) | 2003-05-20 |
US20010031260A1 (en) | 2001-10-18 |
CA2394862A1 (en) | 2001-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT1237575E (pt) | Antagonista de tnf-alfa e antagonista de lfa-1 para tratar a artrite reumatóide | |
MX9602818A (es) | Un metodo de tratamiento de infeccion parasitaria usando antagonistas ige. | |
HK1029595A1 (en) | Cyclic antagonists of c5a receptors and g protein-coupled receptors | |
AU2737102A (en) | Macroheterocylic compounds useful as kinase inhibitors | |
ATE451104T1 (de) | Verfahren zur behandlung oder pruvention von autoimmunkrankheiten mit 2,4-pyrimidindiamin- verbindungen | |
HK1067120A1 (en) | Glutaminyl based dpiv inhibitors | |
HK1057373A1 (en) | Substituted triazole diamine derivatives as kinaseinhibitors | |
IL138476A0 (en) | Method for treating pharmaceutical compositions by special use of anti-oxidant | |
AU2003225295A1 (en) | Substituted pyrroline kinase inhibitors | |
ATE553128T1 (de) | Anti-ngf-antikörper und verfahren zu ihrer verwendung | |
UA85055C2 (ru) | Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний | |
AU2003240517A1 (en) | Substituted pyrrolines as kinase inhibitors | |
YU48698A (sh) | Karboksamidni derivati pirolidina, piperidina i heksahidroazepina za lečenje oboljenja na bazi tromboze | |
YU45102A (sh) | Novi kristalni oblik leflunomida i novi postupci za njegovo dobijanje | |
BG103687A (en) | Atropisomers of 3-heteroaryl-4(3h)-quinazolinones for the treatment of neurodegenerative processes and conditions related to the central nervous system | |
HK1056725A1 (en) | 2-Thio-substituted imidazole derivatives and the use thereof in the pharmaceutical industry. | |
AP2001002248A0 (en) | Method for treating COPD. | |
BG104292A (en) | Methods and compositions for the treatment of rheumatoid arthritis | |
EP1056458A4 (en) | METHODS FOR TREATING PAIN, INCLUDING CHRONIC AND WOMAN-SPECIFIC PAIN | |
IL139303A0 (en) | Treatment of arthritis and other similar conditions | |
EA199800819A1 (ru) | Способ лечения биполярного расстройства | |
AU8680998A (en) | Method for preventing or treating erectile dysfunction by administering an endothelin antagonist | |
EA199800822A1 (ru) | Способ лечения избыточной агрессии | |
GB9619631D0 (en) | Combination therapy | |
UA49490A (uk) | Спосіб лікування ревматоїдного артриту |